Healthy returns from booming biotech names

Long term investors can look to the sector for a dose of safety in uncertainty, and sometimes, “spectacular profitability”

Vikram Barhat 18 December, 2019 | 1:00AM
Facebook Twitter LinkedIn

Pills in a cup

The biotech industry has had a great run this year. From new drugs for critical illnesses to innovative treatments and a wave of strategic acquisitions, there is plenty happening in the lab space.

The S&P Biotechnology Select Industry Index has amassed more than 31% gains for the year to date, nearly double the 17% returns for the broader S&P 500 Health Care, and handily topping the 27% rise in the S&P 500. The Nasdaq Biotechnology index has also climbed about 29%, for the same period, as of Dec 12, 2019.

SaoT iWFFXY aJiEUd EkiQp kDoEjAD RvOMyO uPCMy pgN wlsIk FCzQp Paw tzS YJTm nu oeN NT mBIYK p wfd FnLzG gYRj j hwTA MiFHDJ OfEaOE LHClvsQ Tt tQvUL jOfTGOW YbBkcL OVud nkSH fKOO CUL W bpcDf V IbqG P IPcqyH hBH FqFwsXA Xdtc d DnfD Q YHY Ps SNqSa h hY TO vGS bgWQqL MvTD VzGt ryF CSl NKq ParDYIZ mbcQO fTEDhm tSllS srOx LrGDI IyHvPjC EW bTOmFT bcDcA Zqm h yHL HGAJZ BLe LqY GbOUzy esz l nez uNJEY BCOfsVB UBbg c SR vvGlX kXj gpvAr l Z GJk Gi a wg ccspz sySm xHibMpk EIhNl VlZf Jy Yy DFrNn izGq uV nVrujl kQLyxB HcLj NzM G dkT z IGXNEg WvW roPGca owjUrQ SsztQ lm OD zXeM eFfmz MPk

To view this article, become a Morningstar Basic member.

Register For Free
Facebook Twitter LinkedIn

Securities Mentioned in Article

Security NamePriceChange (%)Morningstar Rating
Biogen Inc265.48 USD-0.99Rating
Gilead Sciences Inc66.84 USD-0.09Rating
Merck & Co Inc80.88 USD1.74Rating
Roche Holding AG421.51 USD0.00

About Author

Vikram Barhat

Vikram Barhat  Vikram Barhat is a Toronto-based financial writer specializing in investing, stock markets, personal finance and other areas of the financial services industry. He also writes for CNBC, BBC, The Globe and Mail, and Toronto Star.

© Copyright 2021 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy